Patent application number | Description | Published |
20120108620 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods. | 05-03-2012 |
20130102781 | METHODS OF MAKING COCRYSTALS - Disclosed are processes for preparing cocrystals, including processes for scaling up of cocrystal formation, as well as scalable processes for preparing cocrystals. Also disclosed are processes for scaled-up preparation of pterostilbene, progesterone, p-coumaric, and minoxidil cocrystals. Minoxidil cocrystals, such as minoxidil:benzoic acid 1:1 monohydrate cocrystals are also disclosed herein. | 04-25-2013 |
20130317225 | NEW FORMS OF RIFAXIMIN AND USES THEROF - The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods. | 11-28-2013 |
20140011828 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 01-09-2014 |
20140073674 | COCRYSTALS OF P-COUMARIC ACID - Disclosed herein are cocrystals of p-coumaric acid and nicotinamide. A 1:1 molar ratio and a 2:1 molar ratio of p-coumaric acid to nicotinamide are herein disclosed. | 03-13-2014 |
20140235595 | COCRYSTALS OF PROGESTERONE - Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein. | 08-21-2014 |
20150216851 | Polymorphs of Cocrystals of p-Coumaric Acid:Nicotinamide - Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms. | 08-06-2015 |
20150299199 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 10-22-2015 |